Floatz logo

GLY-GLY-GLY-CYS-TYR-PHE-GLN-ASN-CYS-PRO-LYS-GLY-NH2 (4-9 DISULFIDE)

Hepatorenal Syndrome

Noorik Biopharmaceuticals AGprotein_peptidePhase 4 / ApprovedActive
A
84/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
76/ 100
Competitive Position
95/ 100

Competitive context

4 Active assets in the Hepatorenal Syndrome cohort.

Asset / SponsorPhaseRating
NORMAL HUMAN SERUM ALBUMIN
Massachusetts General Hospital
Phase 4BBB
Norfloxacin
Hospital Clinic of Barcelona
Phase 4BB
Octreotide Pamoate
University of California, Los Angeles
Phase 2/3BB
Midodrine
University of California, Los Angeles
Phase 2/3BB
[Phe^2,Ile^3,Dab(PhAc-D-Tyr(Me)-Phe-Gln-Asn-Ala-Pro-Arg-iGln-Lys(Ac)-Epsilon-Lys)^8]vasopressin
Ocelot Bio, Inc
Phase 2B

View all 11 →

Same molecule, other indications

GLY-GLY-GLY-CYS-TYR-PHE-GLN-ASN-CYS-PRO-LYS-GLY-NH2 (4-9 DISULFIDE) is also rated in:

cirrhosis of liverDormant
BBB
Indicative ·
77 / 100
View asset →
esophageal varicesDormant
BB
Indicative ·
69 / 100
View asset →
upper digestive tract disorderDormant
BB
Indicative ·
69 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →